Advanced Cell Technology (OTB:[[ticker:ACTC]]), a developer of stem cell treatments, says it has not renewed its lease on a facility in Alameda, CA, and has vacated labs in Boston as part of a plan to cut annual operating expenses by $5 million to $6 million. The company maintains operations in Worcester, MA, and in Los Angeles.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
